Harnessing glycobiology to combat infectious diseases and antimicrobial resistance
Fighting infectious diseases differently
At AIS Biotech, we are developing a new generation of anti-infective biotherapies inspired by nature.
Our mission is to prevent and treat infectious diseases using glycomimetic biotherapeutics that mimic host-cell receptors to neutralize pathogens.
We believe the future of infectious disease management requires:
Our platform is designed to address:
influenza infections yearly
deaths/years by 2050 (AMR projection)
pandemic preparedness needs
Sugar-based decoy receptors to trap pathogens
Many viruses and bacteria infect human cells by binding to specific sugars naturally present at the cell surface.
AIS Biotech develops innovative glycomimetics capable of neutralizing pathogens by mimicking their natural cellular receptors, preventing infection and limiting disease progression.
A scalable glycobiotechnology platform
Using engineered bacterial strains, AIS Biotech produces complex custom oligosaccharides that mimic natural pathogen receptors.
These oligosaccharides are then assembled into multivalent biotherapeutics capable of neutralizing pathogens with high specificity.
Key differenctiators
First-in-class mechanism
Building a pipeline of next-generation anti-infectives
Positioning
Key benefits
Development status
Beyond influenza…
AIS Biotech is leveraging its platform to develop additional anti-infective programs targeting pathogens that rely on sugar-mediated host attachment.
Our platform is already being applied to several high-value infectious disease targets beyond influenza, including viral and bacterial pathogens such as:
Strong concluding sentence
Our platform is designed to rapidly generate new glycomimetic candidates against future emerging infectious threats.
An experienced biotech team
Aurélie Juhem
CEO / co-founder
Marion Pastor
COO/ co-founder
Antoine Rousseau
CTO
Lise Clément- Demange
CSO
Emeline Richard Millot
Scientific Co-founder | Inventor of the Core Technology
Scientific Board / Advisors
Leading scientific experts supporting the development of next-generation anti-infective biotherapies.
Strategic Advisory Board
A team of seasoned executives with extensive experience in biotech financing, partnerships, business development and successful exits.
Jean-Guillaume Lafay
Olivier Le Blainvaux
Kevin Deplanche
